Trial · NCT00826943
Is Levocetirizine Less Sedating Than Cetirizine?
NCT00826943, Phase 4, Completed, Vanderbilt University; results first posted 2014-02-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Is Levocetirizine Less Sedating Than Cetirizine? Trials, record NCT00826943. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00826943
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Is Levocetirizine Less Sedating Than Cetirizine?
- NCT number
- NCT00826943
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 30 participants, actual
- Lead sponsor
- Vanderbilt University
- Conditions
- Allergic Rhinitis
- Interventions
- Cetirizine, Levocetirizine, Placebo
- First posted
- 2009-01-22
- Last updated
- 2014-02-20
- Results first posted
- 2014-02-20
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Modified Epworth Sleepiness Scale | 36 days of the study | Epworth Sleepiness Scale ratings (0 to 24); higher scores = increased sedation. This was measured over the 36 days of the study (at the end of each washout period and each intervention period); measured on days 5, 12, 17, 24, 29, and 36. This was mean data for all interventions. |
| Primary | Likert Score Rating Global Sedation | duration of study (36 days) | Likert score range 1 to 9 (no sedation to extreme sedation). Highers scores indicate increased sedation. This was measured on days days 5, 12, 17, 24, 29, and 36 of the study. This was mean data for all interventions. |
| Secondary | Total Four Symptom Scores (Allergy Symptoms) | same as primary outcome measure (obtain on days 5, 12, 17, 24, 29, and 36) | Total Four Symptom Scores (TFSS) ranging 0 to 12. Increased scores indicate increased symptoms. This was measured on days 5, 12, 17, 24, 29, and 36 of the study. The mean TFSS for patients receiving placebo, cetirizine, and levocetirizine was then calculated. This was mean data for all interventions. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Total Four Symptom Scores (Allergy Symptoms) | same as primary outcome measure (obtain on days 5, 12, 17, 24, 29, and 36) | TFSS scores | MEAN | |
| PRIMARY | Modified Epworth Sleepiness Scale | 36 days of the study | per protocol | units on a scale | MEAN |
| PRIMARY | Likert Score Rating Global Sedation | duration of study (36 days) | per protocol | Likert score | MEAN |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Total Four Symptom Scores (Allergy Symptoms) | Placebo | 4.41 | Standard Deviation 3.76 | TFSS scores | |
| Total Four Symptom Scores (Allergy Symptoms) | Levocetirizine | 3.14 | Standard Deviation 2.67 | TFSS scores | |
| Total Four Symptom Scores (Allergy Symptoms) | Cetirizine | 2.67 | Standard Deviation 2.44 | TFSS scores | |
| Modified Epworth Sleepiness Scale | Placebo | 6.14 | Standard Deviation 4.58 | units on a scale | |
| Modified Epworth Sleepiness Scale | Levocetirizine | 6.69 | Standard Deviation 4.05 | units on a scale | |
| Modified Epworth Sleepiness Scale | Cetirizine | 7.48 | Standard Deviation 5.31 | units on a scale | |
| Likert Score Rating Global Sedation | Placebo | 2.80 | Standard Deviation 1.67 | Likert score | |
| Likert Score Rating Global Sedation | Levocetirizine | 3.07 | Standard Deviation 1.92 | Likert score | |
| Likert Score Rating Global Sedation | Cetirizine | 3.54 | Standard Deviation 2.17 | Likert score |
Source ClinicalTrials.gov
Participant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | L Then C Then P | 6 | |
| Overall Study | STARTED | L Then P Then C | 6 | |
| Overall Study | STARTED | P Then L Then C | 4 | |
| Overall Study | STARTED | P Then C Then L | 5 | |
| Overall Study | STARTED | C Then L Then P | 7 | |
| Overall Study | STARTED | C Then P Then L | 2 | |
| Overall Study | COMPLETED | L Then C Then P | 6 | |
| Overall Study | COMPLETED | L Then P Then C | 6 | |
| Overall Study | COMPLETED | P Then L Then C | 4 | |
| Overall Study | COMPLETED | P Then C Then L | 5 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Levocetirizine | ||
| Total, all-cause mortality | Cetirizine | ||
| Total, other adverse events | Placebo | 0 | 30 |
| Total, other adverse events | Levocetirizine | 0 | 30 |
| Total, other adverse events | Cetirizine | 0 | 30 |
| Total, serious adverse events | Placebo | 0 | 30 |
| Total, serious adverse events | Levocetirizine | 0 | 30 |
| Total, serious adverse events | Cetirizine | 0 | 30 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00826943
GET https://conductscience.org/api/trials/v1/NCT00826943/registered